Trial of Pembrolizumab for Advanced Penile Squamous Cell Carcinoma
Status:
Terminated
Trial end date:
2019-10-01
Target enrollment:
Participant gender:
Summary
Penile squamous cell carcinoma (PSCC) is relatively rare but exhibits higher incidences in
less developed countries. PSCC is a highly aggressive malignancy characterized by early
spread. Pembrolizumab has recently been FDA-approved for the treatment of melanoma but will
serve as the investigational agent for this penile cancer study.